about
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartanWhat can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic reviewHow small is too small? A systematic review of center volume and outcome after cardiac transplantationHeart failure and socioeconomic status: accumulating evidence of inequalityAspirin inhibits the acute arterial and venous vasodilator response to captopril in patients with chronic heart failureA national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in ScotlandDoes aspirin reduce the benefit of an angiotensin-converting enzyme inhibitor? Choosing between the Scylla of observational studies and the Charybdis of subgroup analysisImproved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trialHeart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiologyExplaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine dataPlasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction StudyTemporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland.Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data.Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research DatabasePrior psychiatric hospitalization is associated with excess mortality in patients hospitalized with non-cardiac chest pain: a data linkage study based on the full Scottish population (1991-2006).Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study.Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005.Relationship between alcohol consumption and cardiac structure and function in the elderly: the Atherosclerosis Risk In Communities Study.Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities StudyEfficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH.Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialDetection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patientsGeographic variations in the PARADIGM-HF heart failure trial.Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Heart failure and chronic obstructive pulmonary disease the quandary of Beta-blockers and Beta-agonists.Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction.Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC).Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved EjTen-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart FailurEffects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting: Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF).Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).Falling Cardiovascular Mortality in Heart Failure With Reduced Ejection Fraction and Implications for Clinical Trials.Declining Risk of Sudden Death in Heart Failure.After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction.Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review.
P50
Q26747165-454FD361-295A-409E-9BE2-14201CB54788Q26771479-211A9F8D-F02D-4229-90F7-4194D03CD7D8Q26800965-8268CB83-ED19-46F5-ADF0-CB8A55A36737Q27005975-058CAD09-F124-4482-AB3F-912B3B30CECAQ27012972-05211C3B-3866-4B9B-B650-FC8866FDF09CQ28192202-D3DFF43B-E981-4BC4-B387-69767B95E8D0Q28218708-E2F29A1F-D1F7-43D2-BCF8-D19707A7D30EQ28218799-E5061137-2AA2-4C9C-AA44-FBE06A53FB5FQ28278243-9C34E316-40E2-4452-AA82-E86047850772Q30483582-6311B961-5CA2-4D0F-A7D6-C0141E4EA303Q30750875-F80D4D12-538A-4E50-8C2B-B6374D688CE7Q31036336-DABA0D76-C65C-47E3-8B9D-9C2B87E08469Q33551400-F93A8A46-9DDF-4538-AAF7-E3BF06AC151CQ33624997-5D85F109-73B4-44D5-97BD-C518A60BF0D9Q33873040-2CF02ED4-5213-4475-B358-BAE47AEF7FBFQ34089061-2A2D619C-62DF-4489-BC8A-B8C4EDCF03F1Q34781844-C83B9855-2FE9-4AAA-AD54-E6E1F5D2EE1AQ35060122-643695F0-2C5C-4A3C-9E0D-F90D37D79029Q35692055-61EC4029-2B83-4FFB-983D-20F7DAC550C8Q35784557-C98D7366-ABFC-4E2C-BAB6-47E665AD0907Q36128797-046775DF-4DEA-41E4-A39F-38AA4C0E25B1Q36306239-F2B806BB-4961-4CA0-9FCE-A1168E3DB414Q36477865-E34180FF-E594-48C2-A85A-F90D8029B52EQ37220202-DDC1E382-476C-44A9-9B58-9CBF0F7DB8A6Q37410283-87770E42-64F7-4BFE-AE30-5858B71DA436Q37595978-7773B4F6-5088-496D-A3F5-1B29E605FE83Q37877321-15EDDF26-969A-4A20-882D-5C4218642C84Q37956217-66BEF7B1-5269-429E-BFCF-E3279706B7DCQ38221485-CA72A1B8-BC76-48B9-B5ED-7BCF1A357017Q38382836-C7A5C077-CD93-4F4B-B2A9-94AFA3BA8632Q38385479-378B545E-C9F5-473B-8B4C-D8CD304E1774Q38387656-3F7BA282-36F7-466C-8A56-43D68197790BQ38392958-4E3E9280-5D74-4D17-A7AC-A7B3C104B360Q38409978-DAF2CD7B-D558-497B-BE95-8DCBD3637204Q38422835-10439552-DB26-483B-93D9-406869BCE0F0Q38429596-33BFA049-82AE-48CA-A550-56EEC67ACFBAQ38562230-9B00FD13-8529-41DD-8A7F-ACE3984F5EF4Q38692673-B4E280A8-5F08-44A9-A6D9-B21F471BDDC2Q38807777-A81E24B6-6C15-4D3B-AFF0-C9CD1DB58C69Q38830686-C6FFA8FD-66A7-48BD-AF7B-1252F0339C06
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Pardeep S. Jhund
@ast
Pardeep S. Jhund
@en
Pardeep S. Jhund
@es
Pardeep S. Jhund
@nl
Pardeep S. Jhund
@sl
type
label
Pardeep S. Jhund
@ast
Pardeep S. Jhund
@en
Pardeep S. Jhund
@es
Pardeep S. Jhund
@nl
Pardeep S. Jhund
@sl
altLabel
Pardeep Jhund
@en
prefLabel
Pardeep S. Jhund
@ast
Pardeep S. Jhund
@en
Pardeep S. Jhund
@es
Pardeep S. Jhund
@nl
Pardeep S. Jhund
@sl
P106
P1153
6506826363
P31
P3835
pardeep-jhund
P496
0000-0003-4306-5317